Tabersonine attenuates obesity-induced renal injury via inhibiting NF-κB-mediated inflammation

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Obesity triggers chronic inflammation and metabolic disorders, leading to kidney damage.
• The nuclear factor kappa B (NF-κB) pathway is implicated in obesity-related inflammation and apoptosis.
• Anti-inflammatory agents show promise for preventing obesity-induced renal injury.

Purpose of the Study:

• To evaluate the therapeutic effect of Tabersonine (Tab) on obesity-related renal injury.
• To elucidate the pharmacological mechanism of Tab in ameliorating kidney damage.

Main Methods:

• An obese mouse model induced by a high-fat diet (HFD) was used.
• Tabersonine (20 mg/kg) was administered to assess its effects on renal structure and function.
• In vitro studies utilized a mouse glomerular mesangial cell model exposed to saturated fatty acids.
• NF-κB signaling pathway activation was analyzed both in vivo and in vitro.

Main Results:

• Tabersonine treatment improved renal structure and function in HFD-induced obese mice.
• Tab ameliorated renal tissue fibrosis, reduced renal cell apoptosis, and decreased inflammation.
• Tabersonine inhibited NF-κB pathway activation in both the in vivo and in vitro models.
• The compound protected against HFD- and saturated fatty acid-induced renal cell injury.

Conclusions:

• Tabersonine demonstrates significant therapeutic potential for obesity-related renal injury.
• Inhibition of the NF-κB signaling pathway is a key mechanism underlying Tab's protective effects.
• Tabersonine may serve as a candidate for preventing and treating kidney damage associated with obesity.